Last reviewed · How we verify
ASA evening
Aspirin inhibits platelet aggregation by irreversibly acetylating cyclooxygenase (COX) enzymes, reducing thromboxane A2 production.
Aspirin inhibits platelet aggregation by irreversibly acetylating cyclooxygenase (COX) enzymes, reducing thromboxane A2 production. Used for Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack), Primary prevention of cardiovascular disease in high-risk patients.
At a glance
| Generic name | ASA evening |
|---|---|
| Also known as | ASA, Low dose, aspirine |
| Sponsor | Basque Health Service |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aspirin (acetylsalicylic acid) covalently acetylates COX-1 and COX-2 enzymes in platelets, preventing the synthesis of thromboxane A2, a potent platelet activator and vasoconstrictor. This antiplatelet effect reduces clot formation and is the basis for its use in cardiovascular disease prevention. Evening dosing may optimize circadian effects on platelet function and thrombotic risk.
Approved indications
- Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack)
- Primary prevention of cardiovascular disease in high-risk patients
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Hemorrhagic stroke
- Allergic reactions
Key clinical trials
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (PHASE3)
- Weak Pulse at Yang and Wiry Pulse at Yin Theory (NA)
- Timed Aspirin Chronobiome Study (EARLY_PHASE1)
- Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial (PHASE2, PHASE3)
- Biological Changes Associated With High Risk of Preeclampsia in Nulliparous Women
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (PHASE4)
- Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |